SSR411298 is a reversible, orally active compound that selectively inhibits fatty acid amide hydrolase (FAAH). Its potential lies in the field of post-traumatic stress disorder (PTSD) research.

SSR411298, at concentrations ranging from 0.1 to 10,000 nM, exhibits a concentration-dependent inhibition of mouse brain fatty acid amide hydrolase (FAAH)[1]. In ex-vivo experiments, the compound achieves maximal FAAH inhibition at doses between 0.3 and 30 mg/kg[1].

SSR411298 administered orally at doses of 0.3, 1, and 3 mg/kg twice daily for two days—60 minutes before a pretest, immediately afterward, and 60 minutes before a second testing session—demonstrates significant antidepressant-like effects in both the rat forced-swimming test and the mouse chronic mild stress model. This compound notably reverses the development of inadequate coping responses to chronic stress in male Wistar rats weighing 235-290 g[1]. Additionally, a single dose of SSR411298 (0.3, 1, 3, 10 mg/kg; orally; two hours before euthanasia) significantly increases the levels of tissue AEA, PEA, and OEA in the hippocampus, without affecting 2-AG levels[1].